In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
